{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:01Z","timestamp":1786988041346,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejca.2025.115590","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T11:01:28Z","timestamp":1750762888000},"page":"115590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6246-8862","authenticated-orcid":false,"given":"Viola K.","family":"DeTemple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0650-2576","authenticated-orcid":false,"given":"Martin","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-7286","authenticated-orcid":false,"given":"Yenny","family":"Angela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"von Wasielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-4961","authenticated-orcid":false,"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-114X","authenticated-orcid":false,"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Christoph","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-2072","authenticated-orcid":false,"given":"Franziska","family":"Jochims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9291-1327","authenticated-orcid":false,"given":"Valerie","family":"Glutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-072X","authenticated-orcid":false,"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjd.20964","article-title":"Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study","volume":"186","author":"Kappelin","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/aje\/kwt073","article-title":"Basal-cell carcinoma incidence and associated risk factors in U.S. women and men","volume":"178","author":"Wu","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115590_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5694\/j.1326-5377.2006.tb00086.x","article-title":"Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985","volume":"184","author":"Staples","year":"2006","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2025.115590_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines","volume":"118","author":"Peris","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115590_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"10.1016\/j.ejca.2025.115590_bib6","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115590_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2023.08.111","article-title":"Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up","volume":"90","author":"Stratigos","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115590_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","article-title":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","volume":"35","author":"Lewis","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115590_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejca.2025.115590_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/jid.2013.276","article-title":"Mutational landscape of basal cell carcinomas by whole-exome sequencing","volume":"134","author":"Jayaraman","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115590_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamadermatol.2016.5062","article-title":"Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities","volume":"153","author":"Chang","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115590_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007463","article-title":"Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1\/LAG-3 blockade","volume":"11","author":"Deutsch","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115590_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115590_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.17305\/bjbms.2022.7574","article-title":"Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma","volume":"22","author":"Y\u00fclek","year":"2022","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"10.1016\/j.ejca.2025.115590_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115590_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12885-018-3987-4","article-title":"Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin [published correction appears in","volume":"18","author":"Omland","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2025.115590_bib20","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/ijc.31724","article-title":"Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma","volume":"143","author":"Sternberg","year":"2018","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2025.115590_bib21","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.3390\/cancers14215469","article-title":"Reinduction of hedgehog inhibitors after checkpoint inhibition in advanced basal cell carcinoma: a series of 12 patients","volume":"14","author":"DeTemple","year":"2022","journal-title":"Cancers"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T12:53:15Z","timestamp":1755003195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"alternative-id":["S0959804925003727"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115590","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115590"}}